Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

Young, Helen; Baum, R. P.; Cremerius, U.; Herholz, Karl; Hoekstra, Otto S.; Lammertsma, Adriaan A.; Pruim, Jan; Price, Pat

doi:10.1016/s0959-8049(99)00229-4

Cited by 1,560 publications

(1,133 citation statements)

References 28 publications

Supporting

Mentioning

1,096

Contrasting

Unclassified

Order By: Relevance

“…In (Castaldi et al, 2012), which included 24 patients, no predictive value of PET during treatment was shown. However, the decrease of SUVmax between PET at diagnosis and during treatment was highly correlated with 2-year DFS (100% in case of complete response vs 74% in case of partial response, defined as a reduction of 25% in tumor 18FDG SUV (Young et al, 1999)). …”

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

International audience18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, restaging, radiotherapy planning and monitoring response in many cancers. Quantitative analyses have been introduced in order to overcome some of the limits of the visual methods, allowing an easier and more objective comparison of the inter- and intra-patients variations. The aims of this review were to report available evidences on the clinical value of quantitative PET/CT parameters in HNC. Forty-five studies, for a total of 2928 patients, were analyzed. Most of the data available dealt with the intensity of the metabolism, calculated from the Standard Uptake Value (SUV). Metabolic Tumor Volume (MTV) was well correlated with overall survival and disease free survival, with a higher predictive value than the maximum SUV. Spatial distribution of metabolism and textural analyses seems promising

show abstract

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…Reproducibility studies suggest that changes in SUV >20% are likely to be significant, and current guidelines recommend using a threshold of 25% or 30% for tumors with significant baseline activity. 47,48 However, the SUV thresholds used in clinical studies range from 20% to 70%, with smaller thresholds used for studies performed after a single cycle of chemotherapy and larger thresholds used for studies performed later during the course of treatment. 49 To confound matters, inflammatory tumor changes potentially can blunt the apparent reduction in SUV.…”

Section: Fdg-pet For Monitoring Tumor Responsementioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

196

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

“…Tumor response as evaluated by CT (defined as the categorically assessed CT response) was categorized as CR, PR, SD or PD. Metabolic tumor response (overall) evaluated by FDG-PET/CT (defined as the categorically assessed FDG-PET/CT response) was categorized as complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), or progressive metabolic disease (PMD) [33]. Also, one to three tumor lesions were measured individually before and after two cycles of APF-C and the percent decrease in the total SUV max of the measured lesion(s) was calculated for each patient (defined as the percent decrease in summed SUV max ).…”

Section: Study Design and Definitions Of Tumor Response To Induction mentioning

confidence: 99%

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

Chatzkel¹,

Lewis

Ley³

et al. 2016

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

Cited by 1,560 publications

References 28 publications

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

PET/CT imaging in cancer: Current applications and future directions

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About